⌘+K

Equity Story

Near term

6-12 MONTHS

Vivesto currently lacks the financial resources and internal capabilities required to advance its programmes independently and has therefore initiated partnering discussions across both its veterinary and human health portfolios. Successful transactions could unlock significant value and reduce financing risk. However, partnering processes typically take time and offer limited external visibility, making both the timing and outcome uncertain.

Long term

6+ YEARS

The success of the pipeline remains central to Vivesto's ability to transition into a profitable company with recurring product revenues. However, given the early-stage nature of the portfolio, development risk remains considerable. As a result, future value creation will depend largely on continued clinical de-risking and the company's ability to secure partners capable of funding and advancing the programmes through later-stage development and commercialisation.

Key risks

  • Clinical development of Paccal Vet and Cantrixil is at an early stage, with high risks of setbacks.

  • Competing programmes generating clinical data that could narrow the commercial window for the company’s assets.

  • Securing partnerships would likely provide short- and longer-term financing and important external validation of its assets.

  • If it cannot secure a partner, we see risk of additional financing being needed.

Fair value range

Price

Fair range high value

Fair range low value

The upper end of our fair value range is based on our SOTP analysis, using a WACC of 15%, while the lower end applies a discount rate of 30%. In both scenarios, we anticipate continued progress in its programmes. However, investor sentiment towards biotech remains weak in our lower-end scenario, in which we incorporate an increased financing risk. Our upper-end scenario assumes improved sentiment.

Valuation and methodology

Our valuation of Vivesto is based on a risk-adjusted cash flow model (rNPV), where each project is assessed individually over its patent lifespan and then aggregated in our SOTP model. We focus on the company's active programme, Paccal Vet and Cantrixil.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB